Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.09
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox;...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell